Evidence map›Paper›PMID 27022196›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2016

Cutting Edge: BAFF Promotes Autoantibody Production via TACI-Dependent Activation of Transitional B Cells.

Holly M Jacobs, Christopher D Thouvenel, Sarah Leach, Tanvi Arkatkar, Genita Metzler, Nicole E Scharping, Nikita S Kolhatkar, David J Rawlings, Shaun W Jackson

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Immune response to platelet transfusions.Current opinion in hematology · 2025
    Review
  5. Review
  6. Science translational medicine · 2025
    Article
  7. Autoimmunity in Primary Immunodeficiencies (PID).Clinical reviews in allergy & immunology · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Holly M JacobsSeattle Children's Research Institute, Seattle, WA 98101;ORCID 0000-0003-3250-8258
Christopher D ThouvenelSeattle Children's Research Institute, Seattle, WA 98101;ORCID 0000-0001-8266-975X
Sarah LeachSeattle Children's Research Institute, Seattle, WA 98101;ORCID 0000-0002-1960-5494
Tanvi ArkatkarSeattle Children's Research Institute, Seattle, WA 98101;
Genita MetzlerSeattle Children's Research Institute, Seattle, WA 98101; Department of Immunology, University of Washington School of Medicine, Seattle, WA 98109; and.ORCID 0000-0001-8386-0150
Nicole E ScharpingSeattle Children's Research Institute, Seattle, WA 98101;
Nikita S KolhatkarSeattle Children's Research Institute, Seattle, WA 98101; Department of Immunology, University of Washington School of Medicine, Seattle, WA 98109; and.
David J RawlingsSeattle Children's Research Institute, Seattle, WA 98101; Department of Immunology, University of Washington School of Medicine, Seattle, WA 98109; and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195 drawling@uw.edu shaun.jackson@seattlechildrens.org.ORCID 0000-0002-0810-1776
Shaun W JacksonSeattle Children's Research Institute, Seattle, WA 98101; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195 drawling@uw.edu shaun.jackson@seattlechildrens.org.ORCID 0000-0002-7024-5252
University of Washington · US

Funding

Defining the functional impact of T1D genes in mouse and man: a unified strategyDP3DK097672 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI BUCKNER, JANE HOYT · 2012 to 2013
$4.4M
Lentiviral Gene Therapy for Wiskott-Aldrich SyndromeR01AI071163 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI RAWLINGS, DAVID J · 2008 to 2012
$3.5M
Lentiviral Gene Therapy of X-Linked AgammaglobulinemiaR01AI084457 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI RAWLINGS, DAVID J · 2012 to 2015
$2.5M
Lentiviral Gene Therapy of X-linked AgammaglobulinemiaR01HL075453 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI RAWLINGS, DAVID J · 2004 to 2008
$1.9M
B cell-intrinsic cytokine regulation and B cell-targeted therapies in murine lupuK08AI112993 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI JACKSON, SHAUN WILLIAM · 2014 to 2018
$910k
NHLBI NIH HHS R01 HL075453NIAID NIH HHS K08 AI112993NIAID NIH HHS R01 AI071163NIAID NIH HHS R01 AI084457NIDDK NIH HHS DP3 DK097672
6 · The paper itself

Abstract

Mice overexpressing B cell activating factor of the TNF family (BAFF) develop systemic autoimmunity characterized by class-switched anti-nuclear Abs. Transmembrane activator and CAML interactor (TACI) signals are critical for BAFF-mediated autoimmunity, but the B cell developmental subsets undergoing TACI-dependent activation in settings of excess BAFF remain unclear. We report that, although surface TACI expression is usually limited to mature B cells, excess BAFF promotes the expansion of TACI-expressing transitional B cells. TACI(+) transitional cells from BAFF-transgenic mice are characterized by an activated, cycling phenotype, and the TACI(+) cell subset is specifically enriched for autoreactivity, expresses activation-induced cytidine deaminase and T-bet, and exhibits evidence of somatic hypermutation. Consistent with a potential contribution to BAFF-mediated humoral autoimmunity, TACI(+) transitional B cells from BAFF-transgenic mice spontaneously produce class-switched autoantibodies ex vivo. These combined findings highlight a novel mechanism through which BAFF promotes humoral autoimmunity via direct, TACI-dependent activation of transitional B cells.

Indexed as

AnimalsAutoantibodiesAutoimmunityB-Cell Activating FactorB-Lymphocyte SubsetsLymphocyte ActivationMiceMice, TransgenicPrecursor Cells, B-LymphoidTransmembrane Activator and CAML Interactor ProteinAutoantibodiesB-Cell Activating FactorTnfrsf13b protein, mouseTnfsf13b protein, mouseTransmembrane Activator and CAML Interactor Protein

Identifiers

PMID27022196
PMCPMC4868625
OpenAlexW2327802691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.